Point-of-Care Testing for Diabetes

Critical Care Nursing Quarterly

Volumn 27, Issue 2, 2004, Pages 150-161

  Blake, Deirdre R ^a   Nathan, David M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Diabetes mellitus; Glucose meters; Self monitoring of blood glucose

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; PLASMA PROTEIN;

BLOOD GLUCOSE MONITORING; CLINICAL EXAMINATION; DEVICE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; GLUCOSE URINE LEVEL; HOSPITAL PATIENT; HUMAN; KETONURIA; NON INVASIVE MEASUREMENT; OUTPATIENT CARE; PATIENT MONITORING; PREGNANCY DIABETES MELLITUS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SELF CARE; SELF MONITORING; URINALYSIS;

EID: 2342638423     PISSN: 08879303     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002727-200404000-00007     Document Type: Review

References (58)

1. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus [committee report]. Diabetes Care. 2002;25:S5-S20.
2. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039-1057.
3. World Health Organization. WHO Expert Committee on Diabetes Mellitus. Second Report. Geneva, World Health Org. Tech Rep. Ser. no.646 1980:8-14. Available at: http://www.who.int/dsa/cat97/ztrs.htm.
4. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus [committee report]. Diabetes Care. 1998;21:S5-S19.
5. Modan M, Harris MI. Fasting plasma glucose in screening for NIDDM in the U.S. and Israel. Diabetes Care. 1994;17:436-439.
6. Haffner SM, Rosenthal M, Hazuda HP, Stern MP, Franco LJ. Evaluation of three potential screening tests for diabetes mellitus in a biethnic population. Diabetes Care. 1984;7:347-353.
7. Hanson RL, Nelson RG, McCance DR, et al. Comparison of screening tests for non-insulin-dependent diabetes mellitus. Arch Intern Med. 1993;153:2133-2140.
8. Engelgau MM, Thompson TJ, Smith PJ, et al. Screening for diabetes mellitus in adults. The utility of random capillary blood glucose measurements. Diabetes Care. 1995;18:463-466.
9. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention. The cost-effectiveness of screening for type 2 diabetes. JAMA. 1998;280:1757-1763.
10. American Diabetes Association. Screening for type 2 diabetes [position statement]. Diabetes Care. 2002;25:S21-S24.
11. O'Sullivan J, Mahan CB. Criteria for oral glucose tolerance test in pregnancy. Diabetes. 1964;13:278.
12. Mestman JH. Outcome of diabetes screening in pregnancy and perinatal morbidity in infants of mothers with mild impairment in glucose tolerance. Diabetes Care. 1980;3:447-452.
13. Hadden DR. Geographic, ethnic, and racial variations in the incidence of gestational diabetes mellitus. Diabetes. 1985;34(suppl 2):8-12.
14. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol. 1982;144:768-773.
15. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
16. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304-309.
17. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, II: mortality results. Diabetes. 1970;19:789-830.
18. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
19. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
20. Landon MB, Gabbe SG, Piana R, Mennuti MT, Main EK. Neonatal morbidity in pregnancy complicated by diabetes mellitus: predictive value of maternal glycemic profiles. Am J Obstet Gynecol. 1987;156:1089-1095.
21. Langer O, Mazze R. The relationship between large-for-gestational-age infants and glycemic control in women with gestational diabetes. Am J Obstet Gynecol. 1988;159:1478-1483.
22. Landon MB, Gabbe SG. Glucose monitoring and insulin administration in the pregnant diabetic patient. Clin Obstet Gynecol. 1985;28:496-506.
23. Jovanovic L, Peterson CM, Saxena BB, Dawood MY, Saudek CD. Feasibility of maintaining normal glucose profiles in insulin-dependent pregnant diabetic women. Am J Med. 1980;68:105-112.
24. Peacock I, Hunter JC, Walford S, et al. Self-monitoring of blood glucose in diabetic pregnancy. Br Med J. 1979;2:1333-1336.
25. American Diabetes Association. Standards of medical care for patients with diabetes mellitus [position statement]. Diabetes Care. 2002;25:S33-S49.
26. Walford S, Gale EA, Allison SP, Tattersall RB. Self-monitoring of blood-glucose. Improvement of diabetic control. Lancet. 1978;1:732-735.
27. Sonksen PH, Judd SL, Lowy C. Home monitoring of blood-glucose. Method for improving diabetic control. Lancet. 1978;1:729-732.
28. American Diabetes Association. Self-Monitoring of blood glucose [consensus statement]. Diabetes Care. 1998;19:S62-S66.
29. Oki JC, Flora DL, Isley WL. Frequency and impact of SMBG on glycemic control in patients with NIDDM in an urban teaching hospital clinic. Diabetes Educ. 1997;23:419-424.
30. Newman WP, Laqua D, Engelbrecht D. Impact of glucose self-monitoring on glycohemoglobin values in a veteran population. Arch Intern Med. 1990;150:107-110.
31. Allen BT, DeLong ER, Feussner JR. Impact of glucose self-monitoring on non-insulin-treated patients with type II diabetes mellitus. Randomized controlled trial comparing blood and urine testing. Diabetes Care. 1990;13:1044-1050.
32. Karter AJ, Ackerson LM, Darbinian JA, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes Registry. Am J Med. 2001;111:1-9.
33. Harris MI. Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24:979-982.
34. Franciosi M, Pellegrini F, De Berardis G, et al. The impact of blood glucose self-monitoring on metabolic control and quality of life in type 2 diabetic patients: an urgent need for better educational strategies. Diabetes Care. 2001;24:1870-1877.
35. Wechter DJ, Kaufmann RC, Amankwah KS, et al. Prevention of neonatal macrosomia in gestational diabetes by the use of intensive dietary therapy and home glucose monitoring. Am J Perinatol. 1991;8:131-134.
36. Huddleston JF, Cramer MK, Vroon DH. A rationale for omitting two-hour postprandial glucose determinations in gestational diabetes. Am J Obstet Gynecol. 1993;169(2, pt 1):257-262; discussion 262-264.
37. de Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med. 1995;333:1237-1241.
38. Harris MI, Cowie CC, Howie LJ. Self-monitoring of blood glucose by adults with diabetes in the United States population. Diabetes Care. 1993;16:1116-1123.
39. Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care. 1998;21(suppl 2):B161-B167.
40. Lewandrowski K, Cheek R, Nathan DM, et al. Implementation of capillary blood glucose monitoring in a teaching hospital and determination of program requirements to maintain quality testing. Am J Med. 1992;93:419-426.
41. Lee-Lewandrowski E, Laposata M, Eschenbach K, et al. Utilization and cost analysis of bedside capillary glucose testing in a large teaching hospital: implications for managing point of care testing. Am J Med. 1994;97:222-230.
42. Chmielewski SA. Advances and strategies for glucose monitoring. Am J Clin Pathol. 1995;104(4, suppl 1):S59-S71.
43. Clarke WL, Cox D, Gonder-Frederick LA, Carter W, Pohl SL. Evaluating clinical accuracy of systems for self-monitoring of blood glucose. Diabetes Care. 1987;10:622-628.
44. Klonoff DC. Noninvasive blood glucose monitoring. Diabetes Care. 1997;20:433-437.
45. Kaufman FR, Gibson LC, Halvorson M, Carpenter S, Fisher LK, Pitukcheewanont P. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care. 2001;24:2030-2034.
46. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care. 2001;24:1858-1862.
47. Tamada JA, Garg S, Jovanovic L, Pitzer KR, Fermi S, Potts RO. Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team. JAMA. 1999;282:1839-1844.
48. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
49. Lev-Ran A. Glycohemoglobin. Its use in the follow-up of diabetes and diagnosis of glucose intolerance. Arch Intern Med. 1981;141:747-749.
50. Svendsen PA, Lauritzen T, Soegaard U, Nerup J. Glycosylated hemoglobin and steady-state mean blood glucose concentration in Type 1 (insulin-dependent) diabetes. Diabetologia. 1982;23:403-405.
51. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med. 1984;310:341-346.
52. Boucher BJ, Welch SG, Beer MS. Glycosylated hemoglobins in the diagnosis of diabetes mellitus and for the assessment of chronic hyperglycemia. Diabetologia. 1981;21:34-36.
53. Kobold U, Jeppsson JO, Dulffer T, Finke A, Hoelzel W, Miedema K. Candidate reference methods for hemoglobin A1c based on peptide mapping. Clin Chem. 1997;43:1944-1951.
54. Cagliero E, Levina EV, Nathan DM. Immediate feed-back of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care. 1999;22:1785-1789.
55. Peters AL, Davidson MB, Schriger DL, Hasselblad V, for the Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. JAMA. 1996;276:1246-1252.
56. Davidson MB, Schriger DL, Peters AL, Lorber B. Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA. 1999;281:1203-1210.
57. Edelman SV, Bell JM, Serrano RB, Kelemen D. Home testing of fructosamine improves glycemic control in patients with diabetes. Endocr Pract. 2001;7:454-458.
58. Petitti DB, Contreras R, Dudl J. Randomized trial of fructosamine home monitoring in patients with diabetes. Eff Clin Pract. 2001;4:18-23.